Lung Cancer Metastatic Clinical Trial
Official title:
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
Multiple studies have demonstrated feasibility and safety of delivering cisplatin directly into lung tumors using endobronchial ultrasound guided-transbronchial needle injection (EBUS-TBNI). This technique relies on the use of a bronchoscope with an integrated ultrasound transducer allowing real-time visualization of, and delivery of cisplatin into, tumors lying in proximity to the central airways. Prior work has utilized this technique to treat loco regional recurrence in a previously radiated field. The goal of the current study is to identify the initial dose for intratumoral cisplatin. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05452005 -
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT03179150 -
Clinical Validation of the M5L Lung CAD
|
N/A | |
| Recruiting |
NCT03693339 -
Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation
|
Phase 2 | |
| Completed |
NCT03970564 -
Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer
|
||
| Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
| Terminated |
NCT02308865 -
Early Palliative Care in Metastatic Lung Cancer in Northern France
|
N/A | |
| Not yet recruiting |
NCT03703596 -
Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
|
Phase 2 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Completed |
NCT04233476 -
A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient
|
Phase 3 | |
| Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
| Active, not recruiting |
NCT04986670 -
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
|
N/A | |
| Completed |
NCT03755102 -
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
|
Early Phase 1 | |
| Not yet recruiting |
NCT03638765 -
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT02976740 -
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT04085315 -
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03693326 -
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
|
Phase 2 | |
| Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04964960 -
Pembro+Chemo in Brain Mets
|
Phase 2 | |
| Completed |
NCT04973436 -
DBT for Metastatic Lung Cancer
|
N/A | |
| Recruiting |
NCT05078047 -
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
|
Phase 3 |